FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206466> ?p ?o ?g. }

• W4387206466 endingPage "e120" @default.
• W4387206466 startingPage "e119" @default.
• W4387206466 abstract "Single-session stereotactic radiosurgery (SRS) for large brain metastases (>2cm) results in modest local control. Temporally staged SRS (SSRS), whereby 2 stages of SRS are delivered over a time interval of several weeks, is a novel strategy associated with improved control rates and acceptable radiation necrosis rates. Biomarkers for response are lacking. Here, we report interim results of a phase 1, proof-of-concept study (NCT04689048) to assess the potential clinical utility of amino acid radiotracer 18F-fluciclovine PET/CT as a functional integral biomarker for patients with large brain metastases treated with SSRS.Patients with previously untreated large brain metastases (≥1 lesion; >2cm) underwent a baseline (pre-treatment) 18F-fluciclovine PET/CT and contrast-enhanced treatment planning brain MRI immediately before first SSRS (15 Gy), an interim PET/CT + MRI (4 weeks after the 1st SSRS, immediately prior the 2nd SSRS [15 Gy]), and post-treatment PET/CT + MRI (8 weeks after 2nd SSRS). This interim analysis reviewed the imaging characteristics from static PET images acquired 10-25 minutes after 18F-fluciclovine injection, for the first 7 enrolled patients who completed baseline imaging and 5 who completed the entire treatment course.Seven patients completed baseline imaging and were treated with SSRS for 9 protocol-eligible target lesions, and an additional 25 bystander lesions were treated with SRS. The median age was 72 years and 57% were female. All lesions > 5 mm exhibited baseline increased 18F-fluciclovine uptake compared to the normal contralateral brain. The median baseline target lesion diameters and volumes were 2.16 cm (1.76-3.22 cm) and 4.71cc (2.24-10.21 cc). The median baseline SUVmax, SUVpeak, and SUVmean values were 5.78 (2.16-8.79), 3.33 (0.5-2.72), and 1.75 (1.22-5.16), respectively. The median relative reduction in diameter and volume were both 2% (-13% to 23% and -30% to 60%, respectively) at the interim scans, and at the first follow-up were 30% (-0.2% to 44%) and 43% (-13% to 94%), respectively. Corresponding median relative reduction values for SUVmax, SUVpeak, and SUVmean at interim scans were 20% (-174%-73%), 9% (-99% to 75%), and 14% (-36% to 69%), and at first follow-up 59% (21% to 87%), 41% (-11% to 86%), and 21% (-44% to 79%), respectively. Bystander lesions (< 2 cm) treated with SRS had a median baseline lesion diameter and volume of 0.5 cm (Range: 0.20-1.64 cm) and 0.06 cc (Range: 0.01-1.94 cc). Corresponding median reductions for SUVmax were 5% at interim and 63% at follow-up scans.This proof-of-concept interim study reports baseline 18F-fluciclovine metrics for patients with brain metastases of varying lesion diameters and volumes. Target lesions appear to demonstrate interval reduction in PET metrics after SSRS, more than dimensional measurements alone." @default.
• W4387206466 created "2023-09-30" @default.
• W4387206466 creator A5011399242 @default.
• W4387206466 creator A5012546970 @default.
• W4387206466 creator A5017206877 @default.
• W4387206466 creator A5021021796 @default.
• W4387206466 creator A5033579682 @default.
• W4387206466 creator A5034125535 @default.
• W4387206466 creator A5035416012 @default.
• W4387206466 creator A5038585908 @default.
• W4387206466 creator A5046943288 @default.
• W4387206466 creator A5051693045 @default.
• W4387206466 creator A5062271347 @default.
• W4387206466 creator A5067352155 @default.
• W4387206466 creator A5074838285 @default.
• W4387206466 creator A5079508350 @default.
• W4387206466 creator A5081431641 @default.
• W4387206466 creator A5088040279 @default.
• W4387206466 date "2023-10-01" @default.
• W4387206466 modified "2023-10-17" @default.
• W4387206466 title "Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery (SSRS): Phase 1 Proof-of-Concept Interim Analysis" @default.
• W4387206466 doi "https://doi.org/10.1016/j.ijrobp.2023.06.907" @default.
• W4387206466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784665" @default.
• W4387206466 hasPublicationYear "2023" @default.
• W4387206466 type Work @default.
• W4387206466 citedByCount "0" @default.
• W4387206466 crossrefType "journal-article" @default.
• W4387206466 hasAuthorship W4387206466A5011399242 @default.
• W4387206466 hasAuthorship W4387206466A5012546970 @default.
• W4387206466 hasAuthorship W4387206466A5017206877 @default.
• W4387206466 hasAuthorship W4387206466A5021021796 @default.
• W4387206466 hasAuthorship W4387206466A5033579682 @default.
• W4387206466 hasAuthorship W4387206466A5034125535 @default.
• W4387206466 hasAuthorship W4387206466A5035416012 @default.
• W4387206466 hasAuthorship W4387206466A5038585908 @default.
• W4387206466 hasAuthorship W4387206466A5046943288 @default.
• W4387206466 hasAuthorship W4387206466A5051693045 @default.
• W4387206466 hasAuthorship W4387206466A5062271347 @default.
• W4387206466 hasAuthorship W4387206466A5067352155 @default.
• W4387206466 hasAuthorship W4387206466A5074838285 @default.
• W4387206466 hasAuthorship W4387206466A5079508350 @default.
• W4387206466 hasAuthorship W4387206466A5081431641 @default.
• W4387206466 hasAuthorship W4387206466A5088040279 @default.
• W4387206466 hasConcept C126322002 @default.
• W4387206466 hasConcept C126838900 @default.
• W4387206466 hasConcept C142724271 @default.
• W4387206466 hasConcept C2780387249 @default.
• W4387206466 hasConcept C2780400711 @default.
• W4387206466 hasConcept C2781156865 @default.
• W4387206466 hasConcept C2781464078 @default.
• W4387206466 hasConcept C2989005 @default.
• W4387206466 hasConcept C500558357 @default.
• W4387206466 hasConcept C509974204 @default.
• W4387206466 hasConcept C535046627 @default.
• W4387206466 hasConcept C61943457 @default.
• W4387206466 hasConcept C71924100 @default.
• W4387206466 hasConceptScore W4387206466C126322002 @default.
• W4387206466 hasConceptScore W4387206466C126838900 @default.
• W4387206466 hasConceptScore W4387206466C142724271 @default.
• W4387206466 hasConceptScore W4387206466C2780387249 @default.
• W4387206466 hasConceptScore W4387206466C2780400711 @default.
• W4387206466 hasConceptScore W4387206466C2781156865 @default.
• W4387206466 hasConceptScore W4387206466C2781464078 @default.
• W4387206466 hasConceptScore W4387206466C2989005 @default.
• W4387206466 hasConceptScore W4387206466C500558357 @default.
• W4387206466 hasConceptScore W4387206466C509974204 @default.
• W4387206466 hasConceptScore W4387206466C535046627 @default.
• W4387206466 hasConceptScore W4387206466C61943457 @default.
• W4387206466 hasConceptScore W4387206466C71924100 @default.
• W4387206466 hasIssue "2" @default.
• W4387206466 hasLocation W43872064661 @default.
• W4387206466 hasLocation W43872064662 @default.
• W4387206466 hasOpenAccess W4387206466 @default.
• W4387206466 hasPrimaryLocation W43872064661 @default.
• W4387206466 hasRelatedWork W2115403554 @default.
• W4387206466 hasRelatedWork W2307362100 @default.
• W4387206466 hasRelatedWork W2342601826 @default.
• W4387206466 hasRelatedWork W3093795671 @default.
• W4387206466 hasRelatedWork W3170747497 @default.
• W4387206466 hasRelatedWork W4243001002 @default.
• W4387206466 hasRelatedWork W4288037168 @default.
• W4387206466 hasRelatedWork W4363674280 @default.
• W4387206466 hasRelatedWork W4385578280 @default.
• W4387206466 hasRelatedWork W4386830367 @default.
• W4387206466 hasVolume "117" @default.
• W4387206466 isParatext "false" @default.
• W4387206466 isRetracted "false" @default.
• W4387206466 workType "article" @default.